In 2016, the WHO Classification of Tumours of the Central Nervous System officially recognised that the diagnosis of oligodendrogliomas now required 1p/19q co-deletion in addition to IDH-mutant status [1]. This evidence concerns the gene IDH2 and neoplasm.